NCT03333616 2026-01-21Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer InstitutePhase 2 Active not recruiting100 enrolled
NCT04926181 2025-05-15Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerUniversity of California, San FranciscoPhase 2 Terminated2 enrolled 12 charts